These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 15465797

  • 1. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
    Böger RH.
    J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
    [Abstract] [Full Text] [Related]

  • 2. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH.
    Cardiovasc Res; 2003 Oct 01; 59(4):824-33. PubMed ID: 14553822
    [Abstract] [Full Text] [Related]

  • 3. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH.
    Clin Chem Lab Med; 2003 Nov 01; 41(11):1467-72. PubMed ID: 14656027
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The clinical significance of asymmetric dimethylarginine.
    Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA.
    Annu Rev Nutr; 2006 Nov 01; 26():203-28. PubMed ID: 16848705
    [Abstract] [Full Text] [Related]

  • 9. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA.
    JPEN J Parenter Enteral Nutr; 2008 Nov 01; 32(6):613-21. PubMed ID: 18974239
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
    Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, Bottiglieri T, Lentz SR, Faraci FM.
    Stroke; 2008 Jan 01; 39(1):180-4. PubMed ID: 18063827
    [Abstract] [Full Text] [Related]

  • 11. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production.
    Pope AJ, Karuppiah K, Cardounel AJ.
    Pharmacol Res; 2009 Dec 01; 60(6):461-5. PubMed ID: 19682581
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S, Ueda S, Okuda S.
    Med Hypotheses; 2007 Dec 01; 69(4):922-4. PubMed ID: 17368960
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects.
    Cable DG, Celotto AC, Evora PR, Schaff HV.
    Med Sci Monit; 2009 Sep 01; 15(9):BR248-53. PubMed ID: 19721392
    [Abstract] [Full Text] [Related]

  • 19. ADMA: its role in vascular disease.
    Cooke JP.
    Vasc Med; 2005 Jul 01; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.